- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Novartis will benefit from the acquisition by expanding its radioligand therapy platform, while Endocyte and its shareholders will receive a premium price for the deal.
In an all cash deal, Novartis (NYSE:NVS,SWX:NOVN) has acquired Endocyte (NASDAQ:ECYT) for US$2.1 billion.
Novartis benefits from the acquisition by expanding its radioligand therapy (RLT) platform, while Endocyte and its shareholders will receive a premium price for the deal. Novartis will acquire each share at US$24 — which represents a 54 percent premium in value to its share price at US$15.56 as of market close October 17.
“The global reach and expertise of Novartis in developing and commercializing RLT therapies will be critical in efforts for patients to benefit from these therapies as quickly as possible,” Mike Sherman, CEO of Endocyte, said in the press release.
Endocyte is working with Centerview Partners, Faegre Baker Daniels and Jefferies as lead financial advisor, legal counsel and financial advisor respectively.
According to the release,the transaction is expected to close in the first half of 2019 following approval from Endocyte stockholders, antitrust and regulatory approvals among additional customary closing conditions. The company will continue operating as an independent company until it closes.
Novartis plans to “accelerate development” of Endocyte’s innovative RLT therapies, which have “significant sales potential,” according to the press release.
Endocyte acquired the exclusive worldwide licensing rights to PSMA-617 agents from the private, German-based ABX.
Lu-PSMA-617 is an RLT targeting a specific group of prostate cancer patients. 80 percent of patients in this unique group have metastatic castration-resistant prostate cancer (mCRPC), which may benefit from the treatment. Endocyte is currently enrolling patients for the Phase 3 Vision trial.
Aside from this set of drugs, the company also has two CAR-T programs: one for a bone cancer, while the other is in pre-clinical development.
Novartis is a global company focused on a variety of healthcare needs such as neuroscience, respiratory, oncology, ophthalmology and more.
Investor takeaway
Over the trading period Thursday, investors have shown enthusiasm in the acquisition. Endocyte’s share price increased over 50 percent to US$23.40.
TipRanks shows one analyst, David Nierengarten with Wedbush Securities, downgraded the company from outperform to neutral from the acquisition.
Investors can follow both companies’ news over the next to monitor the acquisition until its close in the first half of 2019. Investors can follow additional information on Endocyte’s website regarding its pipeline and the Vision trial.
Don’t forget to follow@INN_LifeScience for real-time updates!
Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â